Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

Alopecia areata in Spain has a significant impact with unmet treatment needs and high costs.

Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.

The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.

A high neutrophil-to-lymphocyte ratio may predict poor response to hair loss treatment.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

PRP-based treatments can increase hair density, but results vary among individuals.

High-dose IV iron is safe and effective for treating anaemia in IBD patients.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.

Finasteride use may increase suicidality risk, especially in young men.

Baricitinib may help people with long-term alopecia areata.

Systemic treatments like hydroxychloroquine and cyclosporine A help with Lichen Planopilaris and Frontal Fibrosing Alopecia, but ongoing treatment is needed.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Iron supplements may improve hair loss satisfaction even if initial iron levels are normal.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Growth factor concentrate therapy helps manage hair loss.

Antifungal treatment reduced asthma exacerbations and corticosteroid use but its overall benefit is unclear.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

Higher serum ferritin levels than currently used might be needed to rule out iron deficiency in women with hair loss.

The nanocomposite hydrogels can repair themselves, change shape, reduce inflammation, protect against oxidation, kill bacteria, stop bleeding, and help heal diabetic wounds while allowing for wound monitoring.

Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.

Certain drugs can cause eyelid inflammation, so doctors should monitor and educate patients on eyelid care.